Riskpilot← Back to searchSign inGet full accessProPharma Group Sweden AB
ABActiveOrg 5566313036Fleminggatan 18Business and other management consultancy activities · NACE 7020Est. 200255 employees
Revenue 2024
SEK 85,7M
-11% vs 2023
EBITDA margin
-22.2%
-347% vs 2023
Equity ratio
35.1%
Financial strength
Net profit 2024
SEK -8,6M
-1198% vs 2023
| Revenue | SEK 85,7M | -11% |
| EBITDA | SEK -19M | -347% |
| Net profit | SEK -8,6M | -1198% |
| Total assets | SEK 50M | -25% |
| Equity | SEK 17,6M | +73% |
| Employees | 55 | — |
Legal name
ProPharma Group Sweden AB
Org number
5566313036
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
19 augusti 2002
Share capital
SEK 100 000
Employees
55 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas i förening av ledamöterna Firman tecknas ensam av DeGoes, Jason Jon
Company purpose
Bolaget ska tillhandahålla konsulttjänster inom kvalitetssäkring, teknisk support, regulatoriska frågor och biverknins- och säkerhetsfrågor till läkemedels-, medicinteknik- och hälsovårdsindustrin, samt därmed förenlig verksamhet.
Address
Fleminggatan 18
Phone
+468215445
Email
office.se@propharmagroup.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 97 415 | 96 813 | 97 444 | 95 804 | 85 688 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 15 492 | 5 421 | −4 794 | −4 254 | −19 017 |
| Depreciation & amort. | −485 | −323 | −175 | −143 | −114 |
| EBIT | 15 007 | 5 098 | −4 969 | −4 397 | −19 131 |
| Net financials | −286 | −276 | −24 | 265 | −1 437 |
| Profit before tax | 11 022 | 3 622 | −1 167 | −660 | −8 565 |
| Tax | −2 415 | −790 | −0 | −0 | −0 |
| Net profit | 8 607 | 2 832 | −1 167 | −660 | −8 565 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 47 975 | 44 900 | 52 606 | 66 562 | 50 002 |
| Equity | 9 140 | 11 971 | 10 804 | 10 145 | 17 575 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 21 220 | 14 113 | 26 801 | 44 417 | 32 427 |
| Total debt | 21 220 | 14 113 | 26 801 | 44 417 | 32 427 |
EBITDA margin
-22.2%
This company
15.8%
Market median
-241% vs market
20202024
Equity ratio
35.1%
This company
38.2%
Market median
+8% vs market
20202024
Return on equity
-48.7%
This company
18.4%
Market median
-365% vs market
20202024
Net profit margin
-10.0%
This company
8.1%
Market median
-223% vs market
20202024
Asset turnover
1.71×
This company
1.12×
Market median
+53% vs market
20202024
Debt / equity
1.85×
This company
0.62×
Market median
-198% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
JJ Chief Executive Officer | Chief Executive Officer | 2021 |
AC Chief Auditor | Chief Auditor | 2021 |
MH Authorized Recipient of Service | Authorized Recipient of Service | 2022 |
| Former (3) | ||
OC Authorized Recipient of Service | Authorized Recipient of Service | 2021 – 2022 |
EM Chief Executive Officer | Chief Executive Officer | 2021 – 2021 |
JJ Chief Executive Officer | Chief Executive Officer | 2021 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2024 | |
| Board of Directors | 2024 | |
| Former (4) | ||
| Chairman | 2024 – 2024 | |
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2021 – 2024 | |
| Chairman | 2021 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PROPHARMA GROUP EUROPE BV
ProPharma Group Sweden AB Board members of ProPharma Group Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jason Jon DeGoes | Chief Executive Officer | 0 companies |
| Ove Christian Hofling | Authorized Recipient of Service | 0 companies |
| Anneli Christina Richardson | Chief Auditor | 0 companies |
| Eva Marie Lindgren | Chief Executive Officer | 0 companies |
| Maria Helena Johansson | Authorized Recipient of Service | 0 companies |
| Jan Johannes Luijendijk | Chief Executive Officer | 0 companies |
| Karl Vishnu Deonanan | Chairman | 0 companies |
| Brian Stephen Tuttle | Chairman | 0 companies |
| Robert Hugh Chestnut | Board of Directors | 0 companies |
| Timothy Joseph Bauwens | Board of Directors | 0 companies |
| Carl Barker | Board of Directors | 0 companies |
| Dawn Gail Sherman | Chairman | 0 companies |